Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14662635 | 0.83 | ESR1 (0.46) | KCNA5CTSAESR1ATMTDP1 | |
| SCHEMBL17754986 | 0.83 | HTT (0.51) | KCNA5MAPTL3MBTL1HPGDHTT | |
| SCHEMBL17749159 | 0.81 | ADRB2 (0.45) | KCNA5CTSAMAPTRAB9AALDH1A1 | |
| SCHEMBL26455960 | 0.81 | MEN1 (0.48) | KCNA5MAPTRAB9AALDH1A1CYP2C9 | |
| SCHEMBL7112192 | 0.81 | CYP2C19 (0.56) | KCNA5MAPTHTTRAB9AALDH1A1 | |
| SCHEMBL6841260 | 0.80 | FFAR1 (0.49) | CTSA | |
| SCHEMBL12329342 | 0.80 | NR3C2 (0.42) | NR3C2CTSAESR1MAPTTDP1 | |
| SCHEMBL12290664 | 0.80 | NLRP3 (0.47) | NR3C2HTTALDH1A1NLRP3 | |
| SCHEMBL31522456 | 0.79 | ESR1 (0.39) | ESR1MAPTHTTRAB9AALDH1A1 | |
| SCHEMBL7716653 | 0.79 | KCNA5 (0.39) | KCNA5MAPTL3MBTL1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723708-B2 | Anti-HCMV compositions and methods | EVRYS BIO, LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC | 2018-06-21 | — | — | US | disclosed |
| EP-2358716-B1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815875-B2 | Inhibitors of fatty acid binding protein (FABP) | MERCK SHARP & DOHME CORP. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | MERCK SHARP & DOHME LLC | 2011-09-29 | — | — | US | disclosed |
| WO-2010056631-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | SCHERING CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723708-B2 | Anti-HCMV compositions and methods | RPL35, RPL7, RPL5 | NR3C2 2623/4885KCNA5 4837/4885CTSA 51/4885 |
| US-20110237575-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) | FABP4, FABP1, FABP3 | NR3C2 1911/4885KCNA5 3664/4885CTSA 1680/4885 |
| US-20180170884-A1 | ANTI-HCMV COMPOSITIONS AND METHODS | RPL35, RPL7, RPL5 | NR3C2 2623/4885KCNA5 4837/4885CTSA 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.